Palvella Therapeutics PVLA Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax.
The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Palvella Therapeutics's other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Palvella Therapeutics's other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax?
- Palvella Therapeutics (PVLA) reported other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax of $8K in Q1 2026.
- How has Palvella Therapeutics's other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax changed year-over-year?
- Palvella Therapeutics's other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax increased by 233.3% year-over-year, from -$6K to $8K.
- What does other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax mean?
- This represents the net gains or losses resulting from translating the financial statements of foreign subsidiaries into the company's reporting currency. It captures the impact of exchange rate fluctuations on the value of international assets and liabilities. This metric helps investors isolate the effects of currency volatility from core operational performance.